Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial (2019)
- Authors:
- Autor USP: NICOLAU, JOSÉ CARLOS - FM
- Unidade: FM
- DOI: 10.1093/eurheartj/ehz299
- Subjects: INFARTO DO MIOCÁRDIO; INSUFICIÊNCIA CARDÍACA; ENZIMAS PROTEOLÍTICAS; ESTATINAS
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título: European heart journal
- ISSN: 0195-668X
- Volume/Número/Paginação/Ano: v. 40, n. 33, p. 2801-2809, 2019
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
WHITE, Harvey D et al. Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial. European heart journal, v. 40, n. 33, p. 2801-2809, 2019Tradução . . Disponível em: https://doi.org/10.1093/eurheartj/ehz299. Acesso em: 26 jan. 2026. -
APA
White, H. D., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., et al. (2019). Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial. European heart journal, 40( 33), 2801-2809. doi:10.1093/eurheartj/ehz299 -
NLM
White HD, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Erglis A, Goodman SG, Nicolau JC. Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial [Internet]. European heart journal. 2019 ; 40( 33): 2801-2809.[citado 2026 jan. 26 ] Available from: https://doi.org/10.1093/eurheartj/ehz299 -
Vancouver
White HD, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Erglis A, Goodman SG, Nicolau JC. Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial [Internet]. European heart journal. 2019 ; 40( 33): 2801-2809.[citado 2026 jan. 26 ] Available from: https://doi.org/10.1093/eurheartj/ehz299 - P2Y12 inhibitor switching in response to routine notification of CYP2C19 clopidogrel metabolizer status following acute coronary syndromes
- Impact of the Extent of Coronary and Myocardial Disease on the Treatment Effect of Surgical Revascularization in Patients With Ischemic Left Ventricular Dysfunction
- Doença arterial coronariana aguda
- Rationale and design of the long-Term rIsk, clinical manaGement, and healthcare Resource utilization of stable coronary artery dISease in post-myocardial infarction patients (TIGRIS) study
- Ticagrelor versus clopidogrel in patients with STEMI treated with fibrinolysis TREAT trial
- Ticagrelor for the prevention of ischemic events in patients with prior myocardial infarction and peripheral artery disease
- Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel and managed without revascularization: Insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trial
- Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease
- Two-year outcomes among stable high-risk patients following acute MI. Insights from a global registry in 25 countries
- Anti-Thrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC): Study design and methodology for an international, adaptive Bayesian randomized controlled trial
Informações sobre o DOI: 10.1093/eurheartj/ehz299 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
